Selected Grants
CONNECT1905: Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (tocilizumab) for the treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma
Clinical TrialPrincipal Investigator · Awarded by Research Institute at Nationwide Children's Hospital · 2024 - 2029Phase 2 trial of a novel peptide vaccine targeting CMV antigen for newly diagnosed pediatric high grade glioma and diffuse intrinsic pontine glioma and recurrent medulloblastoma
ResearchPrincipal Investigator · Awarded by Food and Drug Administration · 2021 - 2027LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Thera
Clinical TrialPrincipal Investigator · Awarded by Day One Biopharmaceuticals · 2023 - 2027A Phase 1/2, Multicenter, Open-label, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients with Relapsed/Refractory Solid Tumors Harboring a Mutation in KIT or PDGFRA
Clinical TrialPrincipal Investigator · Awarded by Blueprint Medicines Corporation · 2022 - 2027PNOC019 - A Randomized, Blinded, Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Glioma
Clinical TrialPrincipal Investigator · Awarded by The Regents of the University of California · 2025 - 2026PNOC 017: A Target Validation /Phase1 Study of BGB-290 in Combination with Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas
Clinical TrialPrincipal Investigator · Awarded by The Regents of the University of California · 2023 - 2026DAY 101-001, A Phase 2 Study of the Oral pan-RAF Inhibitor DAY101 in Pediatric Patients with BRAF-Mutated Low Grade Glioma
Clinical TrialPrincipal Investigator · Awarded by DOT Therapeutics-1 · 2021 - 2026A Protocol for Children and Young Adults Diagnosed with a Central Nervous System (CNS) Tumor to Assess Cognitive Quality of Life (QOL) and Functional Long-Term effects of Therapies - PNOC COMP
ResearchPrincipal Investigator · Awarded by The Regents of the University of California · 2025 - 2026PNOC022 A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Pr
Clinical TrialPrincipal Investigator · Awarded by The Regents of the University of California · 2024 - 2025PNOC 029, "Nivolumab and DAY101 for the treatment of newly diagnosed or recurrent craniopharyngioma in children and young adults
Clinical TrialPrincipal Investigator · Awarded by The Regents of the University of California · 2023 - 2025Connect 1906 Phase 2 trial of a novel peptide vaccine (PEP-CMV) targeting CMV antigen for newly diagnosed pediatric high-grade glioma and diffuse intrinsic pontine glioma and recurrent medulloblastoma
Clinical TrialCo-Principal Investigator · Awarded by Research Institute at Nationwide Children's Hospital · 2024 - 2025PNOC022 A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial D
Clinical TrialPrincipal Investigator · Awarded by The Regents of the University of California · 2023 - 2024PNOC 019: A Randomized, Double-Blinded, Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Combination Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Glioma (HGG)
Clinical TrialCo-Principal Investigator · Awarded by The Regents of the University of California · 2021 - 2024Phase 2 PVSRIPO and the Checkpoint Inhibitor Pembrolizumab in Recurrent Glioblastoma
Clinical TrialPrincipal Investigator · Awarded by Istari Oncology · 2021 - 2024A Randomized, Multicenter, Phase 2 Study of Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) Alone or in Combination with Lomustine in Recurrent WHO Grade IV Malignant Glioma Patients
Clinical TrialPrincipal Investigator · Awarded by Istari Oncology · 2018 - 2024PNOC022 A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial D
Clinical TrialCo-Principal Investigator · Awarded by The Regents of the University of California · 2022 - 2023Dose-finding and Safety Study of PVSRIPO Against Recurrent WHO Grade IV Malignant Glioma
Clinical TrialPrincipal Investigator · Awarded by Istari Oncology · 2020 - 2022Qualitative Interviews with Recurrent Glioblastoma Patients and their Caregivers
ResearchPrincipal Investigator · Awarded by Istari Oncology · 2021 - 2022PBTC-029
ResearchPrincipal Investigator · Awarded by St. Jude Children's Research Hospital · 2017 - 2022External Relationships
- Dayone biopharmaceuticals
- Eli Lilly & Co.
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.